Status:
COMPLETED
GH and Cardiovascular Risk Factors
Lead Sponsor:
Amsterdam UMC, location VUmc
Conditions:
Growth Hormone Deficiency
Cardiovascular Diseases
Eligibility:
All Genders
20-65 years
Phase:
PHASE4
Brief Summary
Rationale: Abnormally low and high levels of insulin-like growth factor-I (IGF-I) are both associated with increased metabolic risk. Since (U-shaped) associations of IGF-I, within the normal range, ha...
Eligibility Criteria
Inclusion
- Ongoing surveillance at our centre (VUmc)
- Stable substitution therapy for other pituitary hormone deficiencies
Exclusion
- Subjects with a craniopharyngioma as cause of their GHD or pituitary deficiencies
- Contraindications for the use of GH treatment
- (Receiving treatment for) malignant disease (in the past)
- Cardiovascular event less than one year prior to inclusion
- Participation in other studies
- Subjects, who in the opinion of the investigator, are unsuitable in any other way to participate in this study
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT01877512
Start Date
May 1 2013
End Date
April 1 2014
Last Update
May 7 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VU University Medical Center
Amsterdam, PO Box 7057, Netherlands, 1007 MB